Evidence supporting the use of: Sacchoromyces (unspecified)
For the health condition: Thrush
Synopsis
Source of validity: Scientific
Rating (out of 5): 3
Saccharomyces refers to a genus of yeast, with Saccharomyces boulardii being the most studied strain for supporting the treatment of thrush (oral or vaginal candidiasis). Several clinical studies and meta-analyses support its adjunctive use alongside conventional antifungal therapies. S. boulardii is a probiotic yeast that can survive gastric acidity and reach the gut intact, where it has been shown to inhibit the growth of Candida albicans and reduce its adhesion to mucosal surfaces. Mechanistically, S. boulardii may compete with pathogenic yeasts for binding sites, modulate the host’s immune response, and secrete factors that directly inhibit Candida growth or biofilm formation.
A 2017 meta-analysis (Czerucka et al.) found that S. boulardii supplementation reduced the recurrence of various gastrointestinal infections and could be beneficial in reducing Candida colonization, particularly in immunocompromised individuals. However, the evidence is more robust for prevention of recurrence or reduction of colonization, rather than as a sole treatment for active thrush. Additionally, most studies focus specifically on S. boulardii, not other Saccharomyces species.
Therefore, the use of Saccharomyces boulardii as adjunctive therapy for thrush is supported by moderate scientific evidence, particularly in clinical contexts where Candida overgrowth recurs or resists standard treatment. Its role is best seen as supportive, not primary, in treating thrush.
Other health conditions supported by Sacchoromyces (unspecified)
Antibiotics (alternatives to)Antibiotics (side effects of)
Cancer Treatment (reducing side effects)
Chemotherapy (reducing side effects)
Cholesterol (high)
Constipation (adults)
Diarrhea
Digestion (poor)
Gas and Bloating
Infection
Infection (bacterial)
Irritable Bowel Syndrome
Leaky Gut Syndrome
Thrush